LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing’s Syndrome-Reference-Cited by-同舟云学术

LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing’s Syndrome

Published:2023-05 Issue: Volume:228 Page:115316
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Balakirouchenane David^ORCID,Vasseur Axelle,Bonnet-Serrano Fidéline,Choi Minna,Khoudour Nihel,Puszkiel Alicja,Groussin Lionel,Vidal Michel,Declèves Xavier,Bertherat Jérôme,Blanchet Benoit

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference25 articles.

1. Cushing’s syndrome;Lacroix;Lancet,2015

2. Complications of Cushing’s syndrome: state of the art;Pivonello;Lancet Diabetes Endocrinol.,2016

3. Effectiveness of metyrapone in treating Cushing’s Syndrome: a retrospective multicenter study in 195 patients;Daniel;J. Clin. Endocrinol. Metab.,2015

4. Ketoconazole in Cushing’s disease: is it worth a try?;Castinetti;J. Clin. Endocrinol. Metab.,2014

5. Metyrapone treatment in endogenous Cushing’s Syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III/IV study;Nieman;J. Endocr. Soc.,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of osilodrostat in horse urine using LC/ESI–HRMS to establish an elimination profile for doping control;Bioanalysis;2024-09-05

2. Pharmacokinetic study of osilodrostat and identification of mono‐hydroxylated metabolite in equine plasma for the purpose of doping control;Rapid Communications in Mass Spectrometry;2024-01-16

3. Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS/MS;Journal of Pharmaceutical and Biomedical Analysis;2023-10